This inventor holds 7 USPTO granted patents. Top assignee: Eli Lilly and Company. Active years: 2004-2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2004-2008
Title: The Innovative Contributions of David Birenbaum Engel
Introduction
David Birenbaum Engel is a notable inventor based in Bloomington, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of serine protease inhibitors. With a total of seven patents to his name, Engel's work has had a profound impact on the treatment of cardiovascular disorders.
Latest Patents
Engel's latest patents focus on serine protease inhibitors. These compounds, described by the formula (I), are designed to inhibit the serine protease Factor Xa. This inhibition is crucial as it plays a vital role in the treatment of cardiovascular disorders, showcasing Engel's commitment to advancing medical science.
Career Highlights
Engel is currently employed at Eli Lilly and Company, a leading pharmaceutical firm. His work at Eli Lilly has allowed him to collaborate with some of the brightest minds in the industry, further enhancing his contributions to innovative medical solutions.
Collaborations
Some of Engel's notable coworkers include John Walter Liebeschuetz and Christopher William Murray. Their collaborative efforts have undoubtedly enriched the research and development processes within their projects.
Conclusion
David Birenbaum Engel's innovative work in the field of serine protease inhibitors exemplifies his dedication to improving healthcare. His contributions continue to influence the treatment of cardiovascular disorders, marking him as a significant figure in the realm of medical inventions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile